A
ApnimedClinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
3 Pulse stories
TB
Triveni BioTriveni Bio develops genetics-informed antibody and bispecific therapeutics for immunological and inflammatory diseases.
2 Pulse stories
Total Raised
$272M
ApnimedTriveni Bio
Last ValuationNot disclosed
Biotech
Sector
Biotech
2017
Founded
2023
Cambridge, Massachusetts
HQ
Waltham, Massachusetts
Public (APMD)
Status
Private
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Triveni Bio investors
Atlas VentureCormorant Asset ManagementAscenta CapitalJanus Henderson InvestorsDeep Track CapitalOrbiMedViking Global InvestorsFidelity Management & Research
Data from Value Add Pulse coverage and company research — see the full threads for Apnimed and Triveni Bio.